WO2022208171A1 - Procédés de détection d'analytes - Google Patents

Procédés de détection d'analytes Download PDF

Info

Publication number
WO2022208171A1
WO2022208171A1 PCT/IB2022/000179 IB2022000179W WO2022208171A1 WO 2022208171 A1 WO2022208171 A1 WO 2022208171A1 IB 2022000179 W IB2022000179 W IB 2022000179W WO 2022208171 A1 WO2022208171 A1 WO 2022208171A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
protein
aptamer
sample
aptamers
Prior art date
Application number
PCT/IB2022/000179
Other languages
English (en)
Inventor
Sam RODRIQUES
Patrick ARNOTT
Original Assignee
UCL Business Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd. filed Critical UCL Business Ltd.
Publication of WO2022208171A1 publication Critical patent/WO2022208171A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Definitions

  • This disclosure relates to methods and systems for proteomic analysis.
  • free circulating p-Tau proteins have been found to provide a useful measure to diagnose and assess the progression of Alzheimer’s disease, especially in cerebrospinal fluid.
  • concentration of free circulating p-Tau in blood is at attomolar levels, which is too low for conventional methods of quantification and detection.
  • the present disclosure provides systems and methods for detecting and quantifying target analytes in a sample using nucleic acid aptamers. These methods and systems do not require the use or development of antibodies for their implementation. Rather, they leverage robust, sensitive, and readily-deployable nucleic acid amplification and/or sequencing techniques for detection.
  • an aptamer that has complementarity with one or more analyte in a sample is bound to a nucleic acid such that when the analyte binds to the aptamer, the nucleic acid is displaced.
  • the presence and/or amount of the analyte in the sample is determined.
  • Methods and systems of the invention have been shown to provide a limit of detection (LoD) for proteins in a biological sample at a concentration lower than about 40aM and a functional limit of quantification (FLoQ) at a concentration lower than about 2fM.
  • LoD limit of detection
  • FLoQ functional limit of quantification
  • attomolar and femtomolar concentrations are orders of magnitude lower than conventional non antibody-based protein detection assays.
  • the presently- disclosed systems and methods are useful in diagnostic assays, especially those in which detection of minute quantities of analytes, such as proteins, is necessary for timely diagnosis and intervention.
  • the LoD and FLoQ are low, the presently-disclosed methods are effective with smaller, more dilute samples, such as saliva, thus leading to improved non-invasive diagnostic tests.
  • analyte detection with DNA amplification and detection techniques.
  • the analyte is a protein, but it will be apparent to the skilled artisan that any analyte that functions in accordance with the principles of the invention is subject to detection using methods taught herein.
  • the following summary will refer to protein detection, understanding that any analyte that binds an aptamer construct as described herein is detectable using methods of the invention.
  • methods of the invention use target-specific, single-stranded nucleic acid aptamers that are hybridized to a second nucleic acid.
  • the second nucleic acid has regions, both complementary and non-complementary, to the sequence of the aptamer.
  • a target analyte e.g., a protein
  • favorable binding kinetics cause the aptamer to interact with the protein, which displaces the second nucleic acid.
  • the released second nucleic acid is then available for amplification (e.g., qPCR), which is used to detect and/or quantify the target analyte in the sample.
  • a preferred use of the present invention is the detection of proteins or peptides in biological samples, especially samples comprising a heterogenous mix of target and non-target molecules.
  • An exemplary method of the disclosure includes contacting a sample from a subject with a target-specific, single-stranded nucleic acid aptamer that is hybridized to a second nucleic acid with regions complementary to the aptamer. Target proteins in the sample are captured by the aptamers. This capture displaces the second nucleic acid from the aptamer. The second nucleic acid, now free from the aptamer, is amplified for the presence and/or identity of the captured target protein in the sample.
  • Methods of the invention allow detection of a target protein in a sample at or below a concentration of about 40aM.
  • inventive methods are amenable to quantifying the target analyte.
  • the amount of a target protein can be quantified at or below a concentration of about 2fM.
  • Methods of the invention can be multiplexed. For example, a sample is contacted with a plurality of different aptamers that are each bound to a different second nucleic acid.
  • each different target-specific aptamer captures a different target protein and the amplifying step identifies the presence of the different target proteins captured. The amount of these different target proteins can be quantified during the amplification step.
  • the aptamer can be conjugated to a solid surface and can be attached by any appropriate linker, such as biotin/streptavidin, dioxigenein/anti-dioxigenin, FITC/Anti-FITC, thiol/maleimide, amine/NHS, carbohydrate/lectin and other binding combinations.
  • An aptamer for use in the invention can be any aptamer that binds a DNA or RNA sequence of any length.
  • the aptamer may contain modified nucleic acids, such as peptide nucleic acids, locked nucleic acids, and others.
  • the aptamer may be designed to bind an antibody or fragment thereof. In one alternative, the aptamer is replaced by an antibody and the release strand is displaced by antigen binding to the antibody.
  • nucleic acid barcodes such as unique molecular identifiers (UMIs) to enable detection of released nucleic acids.
  • UMIs unique molecular identifiers
  • the invention is also applicable to the identification of aptamers useful for binding a known analyte in a sample.
  • the identification is via the released nucleic acid (second) strand as described above and allows the identification of target-specific aptamers from aptamer libraries for use in assays to detect the analyte.
  • an aptamer library is screened according to the invention in order to identify aptamers that optimally detect specific analytes.
  • Methods of the invention are particularly successful in the detection and/or quantification of a target analyte that is associate with a pathology.
  • the pathology may, for example, be a viral infection and the target protein a viral associated protein.
  • the viral infection is a respiratory virus, such as a severe acute respiratory syndrome (SARS) virus, such as a SARS coronavirus (e.g., SARS-CoV-2).
  • SARS severe acute respiratory syndrome
  • the invention is useful to detect the spike protein present in the SARS-CoV-2 virus.
  • the sample is contacted with a number of different target-specific, single-stranded nucleic acid aptamer that are each hybridized to a different second nucleic acid and capture a different SARS-CoV-2 spike protein isoform or variant.
  • the present disclosure also includes methods in which the pathology is, for example, Alzheimer’s Disease (AD) and the target protein is a p-Tau protein.
  • the amplifying step quantifies the amount of the p-Tau protein in the sample and the method further includes predicting the risk of AD in the subject using the quantified amount of the p-Tau protein.
  • the sample is obtained from one or more of blood, cerebrospinal fluid, semen, fecal matter, saliva, urine, bile, bone marrow, tissue, mucus, tears, and sweat.
  • FIG. 1 provides a schematic overview of a method for detecting and quantifying proteins in a sample.
  • FIG. 2 provides a schematic overview of a method for detecting SARS-CoV-2 spike protein in a sample.
  • FIG. 3 A illustrates the receptor binding domain of the SARS-CoV-2 spike protein interacting with an aptamer of the invention.
  • FIG. 3B provides a closeup view of the SARS-CoV-2 spike protein receptor binding region interacting with the aptamer.
  • FIG. 4 provides gels showing the results of an assay to detect the SARS-CoV-2 spike protein in a sample using the aptamer and release strand of the present invention.
  • FIG. 5 provides gel showing the result of an assay to detect the SARS-CoV-2 spike protein in a sample using the aptamer release strand of the present invention down to 40 aM.
  • FIG. 6 provides a schematic overview of a method to show that the second nucleic acids are displaced from the aptamer by the SARS-CoV-2 spike protein.
  • FIG. 7 provides emission spectrums showing the disassociation of the second nucleic acids from the aptamers due to the aptamer interacting with the SARS-CoV-2 spike protein.
  • the present invention provides systems and methods for detecting and quantifying analytes in a sample using nucleic acid aptamers.
  • the present systems and methods use target- specific, single-stranded nucleic acid aptamers.
  • Each aptamer is hybridized to a second nucleic acid.
  • the second nucleic acids contain regions both complementary and non-complementary to the aptamers.
  • the detection can be via amplification, such as qPCR, followed by sequencing, hybrid capture or any other method for identifying the second nucleic acid.
  • the liberated second nucleic acid is directly sequenced (i.e., without amplification).
  • Methods of the invention have been shown to provide a limit of detection (LoD) for proteins in a sample at a concentration lower than about 40aM and a functional limit of quantification (FLoQ) at a concentration lower than about 2fM.
  • LoD limit of detection
  • FLoQ functional limit of quantification
  • Fig. 1 provides a workflow for an exemplary method 101 of the disclosure for detecting and/or quantifying one or more target analytes in a sample.
  • a sample is exposed to target- specific aptamers.
  • Each aptamer includes a target-specific single-stranded nucleic acid 106.
  • the aptamer is hybridized to a second nucleic 116 acid at regions complementary to the aptamer 114.
  • the aptamer may be attached to a moiety 110, which can be conjugated to a solid surface 112 to anchor the aptamer.
  • the aptamer, nucleic acid, and second nucleic acid have non-complementary regions and/or regions where hybridization is prevented, for example, by using modified nucleotide analogues and/or nonstandard nucleobases.
  • the aptamer captures a target analyte 120 in the sample, displacing the second nucleic acid from the aptamer/nucleic acid.
  • the protein-aptamer complex is optionally removed in a wash step 107.
  • the released, second nucleic acids are then amplified 109 to detect and/or quantify the target protein in the sample. It is only upon displacement from the aptamer that the second, partially complementary nucleic acids become available for an amplification reaction. Thus, amplification of a released second nucleic acid indicates that a target protein was contained in a sample as it bound to the aptamer and displaced the second nucleic acid. Conversely, any aptamer that failed to have its second nucleic acid displaced (i.e., because its target analyte was not in the sample), remains bound to its second nucleic, which is, therefore, not amplified.
  • a sample is contacted with a plurality of the same aptamer.
  • Each aptamer captures the same type of target protein.
  • the second nucleic acids are liberated and subject to detection.
  • the amplification products for each second nucleic acid can be distinguished (e.g., through the use of unique molecular indices). The number of distinct amplification products are used to quantify the amount of the target protein in a sample.
  • a number of different aptamers are used, each capturing a different target protein, and each with a different second nucleic acid. In such cases, the amplification products of the different second nucleic acids are used to identify and quantify different target proteins in a sample.
  • the second nucleic acids are amplified using a polymerase chain reaction (PCR)-based assay to detect the presence of, and quantify the amount of, second nucleic acids displaced from their aptamers.
  • PCR-based assays of interest include, but are not limited to, quantitative PCR (qPCR), quantitative fluorescent PCR (QF-PCR), multiplex fluorescent PCR (MF-PCR), digital droplet PCR (ddPCR) single cell PCR, PCR-RFLP/real time- PCR-RFLP, hot start PCR, nested PCR, in situ polony PCR, in situ rolling circle amplification (RCA), bridge PCR, picotiter PCR, emulsion PCR and reverse transcriptase PCR (RT-PCR).
  • qPCR quantitative fluorescent PCR
  • MF-PCR multiplex fluorescent PCR
  • ddPCR digital droplet PCR
  • hot start PCR hot start PCR
  • nested PCR in situ polony PCR
  • RCA in situ rolling circle amplification
  • ligase chain reaction LCR
  • LAMP loop-mediated isothermal amplification reaction
  • RPA recombinase polymerase reaction
  • transcription amplification self-sustained sequence replication
  • selective amplification of target polynucleotide sequences consensus sequence primed polymerase chain reaction (CP -PCR), arbitrarily primed polymerase chain reaction (AP-PCR), degenerate oligonucleotide-primed PCR (DOP- PCR) and nucleic acid based sequence amplification (NABS A).
  • the amplification reaction is a qPCR method.
  • PCR-based assays can be used to detect the presence of the second nucleic acids in the sample displaced from their aptamers due to a target-protein and aptamer interaction.
  • one or more primers specific to a particular second nucleic acid are used for amplification. These primers have sequences specific to a particular second nucleic acid such that they only hybridize and initiate PCR when they are complementary to a second nucleic acid. If the second nucleic acid of interest is present in the sample and has been displaced from its aptamer, the primer will hybridize for an amplification reaction.
  • the PCR products may be detected to identify and quantitate the target protein in the sample.
  • the PCR product can be detected, for example, by methods using an intercalating dye, like SybrGreen or ethidium bromide, hybridizing the PCR products to a solid substrate, such as a bead (e.g., magnetic or fluorescent beads, such as Luminex beads), or detecting them through an intermolecular reaction, such as FRET, or sequence-specific detection methods such as TaqMan probes, molecular beacons or scorpion probes.
  • an intercalating dye like SybrGreen or ethidium bromide
  • a solid substrate such as a bead (e.g., magnetic or fluorescent beads, such as Luminex beads)
  • FRET intermolecular reaction
  • sequence-specific detection methods such as TaqMan probes, molecular beacons or scorpion probes.
  • the second nucleic acids may include a PCR handle that functions as a primer site used for subsequent PCR amplification. Accordingly, the inclusion of PCR-handle-specific primers during amplification of the released second nucleic acids.
  • the second nucleic acids comprise a universal primer sequence and are amplified using a universal primer.
  • the term “universal primer sequence” generally refers to a primer binding site, e.g., a primer sequence that would be expected to hybridize (base- pair) to, and prime, one or more loci of complementary sequence, if present, on any nucleic acid fragment.
  • the universal primer sequences used with respect to the present methods are P5 and P7.
  • the amplified second nucleic acids are used to construct a library.
  • Certain methods of the invention include, for example, counting second nucleic acids amplified in the library.
  • counting may include any of the following: counting the total number of amplified targets; comparing the number of targets amplified to the number of different aptamers; comparing the absolute or relative abundance of different amplified targets; and counting the number of target products that arose from independent amplification of the same second nucleic acid molecule.
  • Methods of the disclosure may further include sequencing amplified second sequences in the library. Sequencing can be used, for example, to identifying and quantify the released second nucleic acids. In certain aspects, amplification products of the second sequences are sequenced for purposes of identification and/or quantification.
  • the second nucleic acid includes one or more barcode regions.
  • the term barcode region may comprise any number of barcodes, index or index sequence, UMIs, which are unique, i.e., distinguishable from other barcode, or index, UMI sequences.
  • the sequences may be of any suitable length which is sufficient to distinguish the barcode, or index, sequence from other barcode sequences.
  • a barcode, or index, sequence may have a length of 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides, or more.
  • the barcodes, or indices are predefined and selected at random.
  • a barcode may comprise unique molecular identifiers (UMIs).
  • UMIs are a type of barcode that may be provided to a sample to make each nucleic acid molecule, together with its barcode, unique, or nearly unique. This may be accomplished by adding one or more UMIs to the second nucleic acids. By selecting an appropriate number of UMIs, every second nucleic acid molecule in the sample, together with its UMI, will be unique or nearly unique.
  • UMIs can be used to quantify the number of individual released second nucleic acids, and by extension, the aptamers to which they were hybridized and the analytes (e.g., proteins) that displaced the second nucleic acids.
  • sequences with identical UMI sequences may be considered to refer to the same starting nucleic acid molecule.
  • sequence data e.g., sequence reads
  • the de-duplicated sequence data represents quantity or number of unique starting second nucleic acids before amplification and sequencing.
  • UMIs are also advantageous in that they can be used to correct for errors created during amplification, such as amplification bias or incorrect base pairing during amplification.
  • errors created during amplification such as amplification bias or incorrect base pairing during amplification.
  • UMIs because every nucleic acid molecule in a sample together with its UMI or UMIs is unique or nearly unique, after amplification, molecules with identical sequences may be considered to refer to the same starting nucleic acid molecule, thereby reducing amplification bias.
  • the invention may include detecting changes in target proteins indicative of a disease or medical condition.
  • the methods may include providing a diagnosis, prognosis, or course of treatment for a disease or medical condition.
  • the aptamer is a single-stranded nucleic acid about 20 bases in length. In certain aspects, the aptamer is a single-stranded nucleic acid between 5-10 bases in length, 10- 20 bases in length, 20-30 bases in length, 30-40 bases in length, 40-50 bases in length, 50-60 bases in length, 60-70 bases in length, 70-80 bases in length, 80-90 bases in length, or 90-100 bases in length.
  • the single-stranded nucleic acids of the aptamers are designed to exhibit kinetics favorable to disassociating in the presence of the target analyte.
  • the aptamers may be designed using techniques such as Systematic Evolution of Ligands by Exponential Enrichment (SELEX).
  • SELEX Systematic Evolution of Ligands by Exponential Enrichment
  • a library of nucleic acids is prepared, with each having a target binding region composed of random nucleobases.
  • the nucleic acids are contacted with a target protein. Nucleic acids bound to the target proteins are eluted, while unbound nucleic acids are discarded. The eluted nucleic acids are amplified.
  • the eluted nucleic acids are contacted with proteins similar to the target protein. Nucleic acids that bind to these similar proteins are discarded.
  • the remaining nucleic acids are sequenced and their K d determined.
  • nucleic acids with an appropriate K d are selected for use as aptamers.
  • the sample may be derived from live cells, for example, a tissue or body fluid sample of a human or non-human animal subject.
  • the sample may be obtained via a fine needle aspirate, a biopsy, or body fluid collection, such as an effluent or discharge fluid.
  • the sample includes or is derived from one or more of blood, plasma, cerebrospinal fluid, semen, fecal matter, saliva, urine, bile, bone marrow, tissue, mucus, tears, and sweat.
  • the sample is obtained by minimally-invasive means.
  • target proteins for detection are derived from circulating cells, cellular components, extracellular vesicles, exosomes, antigens, prokaryotic cells, fungi, viruses, and/or combinations thereof.
  • the invention is useful for the detection of circulating tumor cells, fetal cellular material or any other material amenable to detection in a liquid biopsy format.
  • the protein is a viral protein, a bacterial protein, or other protein associated with a pathology.
  • the pathology is Alzheimer’s disease and the target protein is a p- tau protein.
  • the target protein is indicative of a disease, such as cancer.
  • the target protein contains a mutation or misfolding indicative of a genetic alterations, including substitutions, insertions, deletions, truncations, single nucleotide polymorphisms, changes in copy number, changes in expression, and the like.
  • the initial binding construct of the second nucleic acid may be used to screen libraries of unknown aptamers to select the most appropriate combination of aptamer and second nucleic acid to favor the kinetics in the selection of aptamers used in the invention.
  • Methods of the disclosure may include any known sequencing technique to identify and/or quantify the second nucleic acids.
  • a sequencing technique that can be used in the methods of the invention includes any of those commercialized by Illumina, such as those described in U.S. Pat. Nos. 5,750,341; 6,306,597; and 5,969,119, which are each incorporated by reference.
  • directional (strand-specific) libraries are prepared, and the selected single-stranded nucleic acid is amplified, for example, by PCR.
  • the resulting nucleic acid is then denatured and the single- stranded amplified polynucleotides are randomly attached to the inside surface of flow-cell channels. Unlabeled nucleotides are added to initiate solid-phase bridge amplification to produce dense clusters of double-stranded DNA.
  • first base sequencing cycle To initiate the first base sequencing cycle, four labeled reversible terminators, primers, and DNA polymerase are added. After laser excitation, fluorescence from each cluster on the flow cell is imaged. The identity of the first base for each cluster is then recorded. Cycles of sequencing are performed to determine the fragment sequence one base at a time.
  • the methods of the present invention may employ sequencing by ligation methods commercialized by Applied Biosystems (e.g., SOLiD sequencing).
  • the methods of the present invention may employ sequencing by synthesis using the methods commercialized by 454/Roche Life Sciences, including but not limited to the methods and apparatus described in Margulies et al., Nature (2005) 437:376-380 (2005); and U.S. Pat. Nos. 7,244,559; 7,335,762; 7,211,390; 7,244,567; 7,264,929; and 7,323,305.
  • the methods of the present invention may employ the sequencing methods commercialized by Helicos BioSciences Corporation (Cambridge, Mass.), such as described in U.S. application Ser. No.
  • a nanopore can be a small hole of the order of 1 nanometer in diameter. Immersion of a nanopore in a conducting fluid and application of a potential across it can result in a slight electrical current due to conduction of ions through the nanopore. The amount of current that flows is sensitive to the size of the nanopore. As a DNA or label molecule passes through a nanopore, each nucleotide on, or label from, the DNA molecule obstructs the nanopore to a different degree. Thus, the change in the current passing through the nanopore as the DNA molecule or label passes through the nanopore can represent a reading of the DNA sequence.
  • Ion Torrent e.g., using the Ion Personal Genome Machine (PGM)
  • Ion Torrent technology can use a semiconductor chip with multiple layers, e.g., a layer with micro-machined wells, an ion-sensitive layer, and an ion sensor layer.
  • Nucleic acids can be introduced into the wells, e.g., a clonal population of single nucleic can be attached to a single bead, and the bead can be introduced into a well.
  • one type of deoxyribonucleotide e.g., dATP, dCTP, dGTP, or dTTP
  • dATP dATP
  • dCTP dCTP
  • dGTP dGTP
  • dTTP deoxyribonucleotide
  • protons hydrogen ions
  • the semiconductor chip can then be washed and the process can be repeated with a different deoxyribonucleotide.
  • a plurality of nucleic acids can be sequenced in the wells of a semiconductor chip.
  • the semiconductor chip can comprise chemical-sensitive field effect transistor (chemFET) arrays to sequence DNA (for example, as described in U.S. Patent Application Publication No.
  • chemFET chemical-sensitive field effect transistor
  • Sequencing generally produces sequencing data, such as sequence reads, that can be used to identify and quantify the released second nucleic acids. Sequencing produces sequence data that can be assembled or analyzed in accordance with known methods, such as those discussed in U.S. Patent No. 8,209,130, incorporated by reference.
  • the present Inventors performed a proof-of-principle experiment that shows the presently disclosed systems and methods are able to accurately detect the presence of the SARS-CoV-2 viral proteins when present in a sample at attomolar concentrations.
  • Fig. 2 provides a schematic of the experiment.
  • the single-stranded nucleic acid aptamers (Cv2 A) were hybridized to a release strand of nucleic acid and were anchored to a solid surface via a biotin/streptavidin interaction.
  • the aptamer included a sequence with sites that bind to the SARS-CoV-2 spike protein.
  • the SARS-CoV-2 spike protein was added to a solution containing the aptamers at different concentrations.
  • the aptamers bound the spike proteins in the samples, displacing the second nucleic acid (Cv2 comp) from the aptamers.
  • the solid surface was washed to remove the released second nucleic acid, which was collected and amplified to detect the presence and quantity of the spike protein in each sample.
  • the amplified products were collected, fluorescently labeled, and run on gels in a 10% Native PAGE assay at 170 V for 35 minutes.
  • Fig. 3A shows the structure of the SARS-CoV-2 spike protein, with its receptor binding domain (RBD) highlighted.
  • the nucleic acid aptamer (2019nCoV-RBD-lC) is shown interacting with the RBD of the spike protein.
  • Fig. 3B provides a closeup view of the protein-aptamer interaction. As shown, several amino acids in the protein RBD interact with and/or form bonds with bases in the nucleic acid aptamer.
  • Fig. 4 provides pictures of the gels, each gel representing a separate repetition of the experiment.
  • the lanes of the gels each included:
  • Lane 7 Amplified products from SAR.S-CoV-2 spike protein at 400 aM
  • the positive control (Lane 2) was the second nucleic acid free from aptamers.
  • the bright band at about 100 base pairs reveals that these second nucleic acids were available for amplification.
  • the negative control, Lane 8, was from an assay run in which the aptamer was attached to the solid surface, but not hybridized to a second nucleic acid. The lack of the 100 base pair band in lane 8 confirms that the second nucleic acid was not in the sample and available for amplification.
  • Lanes 2-7 of each gel contain the amplification products of the second nucleic acids after contacting the aptamers with SAR.S-CoV-2 spike proteins at various concentrations.
  • the lowest concentration of spike protein tested was at 400 aM (Lane 7).
  • the second nucleic acid was successfully and specifically displaced and amplified despite the miniscule concentrations of spike protein.
  • the amount of spike protein in the lowest concentration aliquots (400 aM) was quantified, which provided preliminary results of approximately 1,200 molecules of spike protein detected in the sample.
  • the spike protein of SARS-CoV-2 is a trimer, thus the 1,200 molecules quantified represent the equivalent of 400 trimers. Given the average number of turners per virus particle, the presently disclosed method was able to quantify an amount of spike protein equivalent to only about 16 viral particles.
  • the presently-disclosed methods are able to detect and quantify viral proteins with high specificity at an unprecedently low concentration.
  • Fig. 5 provides a picture of a gel showing results from separate repetitions of the experiment.
  • the positive controls (Lane 3 and 10) are the second nucleic acid free from aptamers.
  • the bright band at about 100 base pairs reveals that the released second nucleic acids were available for amplification.
  • the negative control, Lane 7, was from an assay run in which the aptamer was attached to the solid surface and hybridized to its complementary strand and was contacted with a vehicle solution without target protein present.
  • the lack of the 100 base pair band in lane 7 confirms that the second nucleic acid was not in the sample and available for amplification.
  • Lanes 4-6 of the gel contain the amplification products of the second nucleic acids after contacting the aptamers with SARS-CoV-2 spike proteins at various concentrations.
  • the lowest concentration of spike protein that registered a detection was at 40 aM (Lane 5), as shown by the band at around 100 base pairs in the lane.
  • the present Inventors performed an experiment showing that the second nucleic acid is displaced from the aptamer by the SARS-CoV-2 spike protein as expected.
  • Fig. 6 provides an overview of the experiment 601.
  • An aptamer 603 was prepared and anchored to a solid surface 607.
  • the second nucleic acid used in Example 1 was, in essence, split apart to form nucleic acids PI and P2.
  • PI was decorated with a Cy5 fluorophore and P2 with a Cy3 fluorophore.
  • P2 and P3 hybridized to the aptamer, including at a location on the aptamer that interacts with the spike protein.
  • the Cy5 and Cy3 fluorophores were disposed from one another at a distance to cause a Forster resonance energy transfer interaction between the fluorophores.
  • the aptamer was then contacted with the spike protein.
  • Fig. 7 shows an emission spectrum for repetitions of the experiment 601.
  • the spike protein was provided at a concentration of 83 nM and in the second at 1 mM.
  • the dark line represents the spectrum taken after contacting the aptamers with the spike protein.
  • the increase in emission at approximately 650 nm indicates that the Cy3 of P2 was removed from its proximity to the Cy5 of PI. This indicates that the PI and P2 displaced.
  • P2 hybridized to the aptamer at a location suspected of binding to the spike protein it is clear that PI and P2 were displaced due to the aptamer-protein interaction.
  • AD Alzheimer’s Diseases
  • CSF cerebral spinal fluid
  • Assays to detect p-taul81 in plasma represent a potential alternative to CSF-based screening, but levels of p-taul81 in the blood are very low, and to date there are no clinically approved assays for p-taul81 in blood.
  • a plasma sample is obtained from a subject.
  • Target-specific, single-stranded nucleic acid aptamers each hybridized to a second nucleic acid, are introduced into the sample.
  • the aptamers have a nucleic acid sequence that interacts with one of p-taul81, p-tau202, and p-tau441.
  • the second nucleic acid is displaced.
  • the released second nucleic acids are collected and amplified to identify and quantify p-tau isoforms in the sample.
  • the quantity of p-tau isoforms in the sample is used to predict the progression or onset of AD in the subject.
  • the p-tau isoforms are detected at an LoD of about 0.002 pg/mL (40aM) and quantified at a FLoQ of about 0.1 pg/mL (2fM).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des systèmes de détection et de quantification de protéines dans un échantillon à l'aide d'aptamères d'acides nucléiques simple brin.
PCT/IB2022/000179 2021-03-31 2022-03-29 Procédés de détection d'analytes WO2022208171A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163168836P 2021-03-31 2021-03-31
US63/168,836 2021-03-31

Publications (1)

Publication Number Publication Date
WO2022208171A1 true WO2022208171A1 (fr) 2022-10-06

Family

ID=81927492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/000179 WO2022208171A1 (fr) 2021-03-31 2022-03-29 Procédés de détection d'analytes

Country Status (1)

Country Link
WO (1) WO2022208171A1 (fr)

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US20060024711A1 (en) 2004-07-02 2006-02-02 Helicos Biosciences Corporation Methods for nucleic acid amplification and sequence determination
US20060024678A1 (en) 2004-07-28 2006-02-02 Helicos Biosciences Corporation Use of single-stranded nucleic acid binding proteins in sequencing
US20060286566A1 (en) 2005-02-03 2006-12-21 Helicos Biosciences Corporation Detecting apparent mutations in nucleic acid sequences
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7244567B2 (en) 2003-01-29 2007-07-17 454 Life Sciences Corporation Double ended sequencing
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7276720B2 (en) 2004-07-19 2007-10-02 Helicos Biosciences Corporation Apparatus and methods for analyzing samples
US7302146B2 (en) 2004-09-17 2007-11-27 Pacific Biosciences Of California, Inc. Apparatus and method for analysis of molecules
US20080087826A1 (en) 2004-11-16 2008-04-17 Helicos Biosciences Corporation Optical train and method for tirf single molecule detection and analysis
US20080103058A1 (en) 2006-04-26 2008-05-01 Helicos Biosciences Corporation Molecules and methods for nucleic acid sequencing
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US20080206764A1 (en) 2000-06-07 2008-08-28 Pacific Biosciences Flowcell system for single molecule detection
US20080213770A1 (en) 1998-05-01 2008-09-04 Helicos Biosciences Corporation Method of Determining The Nucleotide Sequence of Oligonucleotides and DNA Molecules
US7462452B2 (en) 2004-04-30 2008-12-09 Pacific Biosciences Of California, Inc. Field-switch sequencing
US7462468B1 (en) 2005-01-28 2008-12-09 Pacific Biosciences Of California, Inc. DNA intercalating agents and methods of use
US7476504B2 (en) 2005-01-31 2009-01-13 Pacific Biosciences Of California, Inc. Use of reversible extension terminator in nucleic acid sequencing
US20090024331A1 (en) 2007-06-06 2009-01-22 Pacific Biosciences Of California, Inc. Methods and processes for calling bases in sequence by incorporation methods
US20090029385A1 (en) 2007-07-26 2009-01-29 Pacific Biosciences Of California, Inc. Molecular redundant sequencing
US20090026082A1 (en) 2006-12-14 2009-01-29 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
US7491498B2 (en) 2003-11-12 2009-02-17 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US20090061439A1 (en) 2007-05-03 2009-03-05 Helicos Biosciences Corporation Methods and Compositions for Sequencing A Nucleic Acid
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US20090068655A1 (en) 2003-04-08 2009-03-12 Pacific Biosciences Composition and method for nucleic acid sequencing
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969119A (en) 1995-04-17 1999-10-19 Lynx Therapeutics, Inc. DNA sequencing by parallel olgonucleotide extensions
US6306597B1 (en) 1995-04-17 2001-10-23 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US20080213770A1 (en) 1998-05-01 2008-09-04 Helicos Biosciences Corporation Method of Determining The Nucleotide Sequence of Oligonucleotides and DNA Molecules
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US7264929B2 (en) 1999-09-16 2007-09-04 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7335762B2 (en) 1999-09-16 2008-02-26 454 Life Sciences Corporation Apparatus and method for sequencing a nucleic acid
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US20080206764A1 (en) 2000-06-07 2008-08-28 Pacific Biosciences Flowcell system for single molecule detection
US7244567B2 (en) 2003-01-29 2007-07-17 454 Life Sciences Corporation Double ended sequencing
US7323305B2 (en) 2003-01-29 2008-01-29 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
US20090068655A1 (en) 2003-04-08 2009-03-12 Pacific Biosciences Composition and method for nucleic acid sequencing
US7491498B2 (en) 2003-11-12 2009-02-17 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7462452B2 (en) 2004-04-30 2008-12-09 Pacific Biosciences Of California, Inc. Field-switch sequencing
US20060024711A1 (en) 2004-07-02 2006-02-02 Helicos Biosciences Corporation Methods for nucleic acid amplification and sequence determination
US7276720B2 (en) 2004-07-19 2007-10-02 Helicos Biosciences Corporation Apparatus and methods for analyzing samples
US20060024678A1 (en) 2004-07-28 2006-02-02 Helicos Biosciences Corporation Use of single-stranded nucleic acid binding proteins in sequencing
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
US7476503B2 (en) 2004-09-17 2009-01-13 Pacific Biosciences Of California, Inc. Apparatus and method for performing nucleic acid analysis
US7302146B2 (en) 2004-09-17 2007-11-27 Pacific Biosciences Of California, Inc. Apparatus and method for analysis of molecules
US7313308B2 (en) 2004-09-17 2007-12-25 Pacific Biosciences Of California, Inc. Optical analysis of molecules
US7315019B2 (en) 2004-09-17 2008-01-01 Pacific Biosciences Of California, Inc. Arrays of optical confinements and uses thereof
US20080087826A1 (en) 2004-11-16 2008-04-17 Helicos Biosciences Corporation Optical train and method for tirf single molecule detection and analysis
US7462468B1 (en) 2005-01-28 2008-12-09 Pacific Biosciences Of California, Inc. DNA intercalating agents and methods of use
US7476504B2 (en) 2005-01-31 2009-01-13 Pacific Biosciences Of California, Inc. Use of reversible extension terminator in nucleic acid sequencing
US20060286566A1 (en) 2005-02-03 2006-12-21 Helicos Biosciences Corporation Detecting apparent mutations in nucleic acid sequences
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US20080103058A1 (en) 2006-04-26 2008-05-01 Helicos Biosciences Corporation Molecules and methods for nucleic acid sequencing
US20090026082A1 (en) 2006-12-14 2009-01-29 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
US20090061439A1 (en) 2007-05-03 2009-03-05 Helicos Biosciences Corporation Methods and Compositions for Sequencing A Nucleic Acid
US20090024331A1 (en) 2007-06-06 2009-01-22 Pacific Biosciences Of California, Inc. Methods and processes for calling bases in sequence by incorporation methods
US20090029385A1 (en) 2007-07-26 2009-01-29 Pacific Biosciences Of California, Inc. Molecular redundant sequencing
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CHINNAPPAN RAJA ET AL: "An aptamer based fluorometric microcystin-LR assay using DNA strand-based competitive displacement", MICROCHIMICA ACTA, SPRINGER VIENNA, VIENNA, vol. 186, no. 7, 13 June 2019 (2019-06-13), pages 1 - 10, XP036806173, ISSN: 0026-3672, [retrieved on 20190613], DOI: 10.1007/S00604-019-3504-8 *
DENG BIN ET AL: "Aptamer binding assays for proteins: The thrombin example-A review", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 837, 21 July 2014 (2014-07-21), pages 1 - 15, XP028862975, ISSN: 0003-2670, [retrieved on 20140502], DOI: 10.1016/J.ACA.2014.04.055 *
FEAGIN TREVOR A. ET AL: "Strategies for Creating Structure-Switching Aptamers", ACS SENSORS, vol. 3, no. 9, 28 September 2018 (2018-09-28), US, pages 1611 - 1615, XP055956613, ISSN: 2379-3694, DOI: 10.1021/acssensors.8b00516 *
GU HUAJIE ET AL: "A competitive fluorescent aptasensor for okadaic acid detection assisted by rolling circle amplification", MICROCHIMICA ACTA, SPRINGER VIENNA, VIENNA, vol. 184, no. 8, 10 May 2017 (2017-05-10), pages 2893 - 2899, XP036281636, ISSN: 0026-3672, [retrieved on 20170510], DOI: 10.1007/S00604-017-2293-1 *
HUANG GUOLIANG ET AL: "fM to aM nucleic acid amplification for molecular diagnostics in a non-stick-coated metal microfluidic bioreactor", SCIENTIFIC REPORTS, vol. 4, no. 1, 5 December 2014 (2014-12-05), XP055956748, Retrieved from the Internet <URL:https://www.nature.com/articles/srep07344.pdf> DOI: 10.1038/srep07344 *
LI FENG ET AL: "Aptamers Facilitating Amplified Detection of Biomolecules", ANALYTICAL CHEMISTRY, vol. 87, no. 1, 6 January 2015 (2015-01-06), US, pages 274 - 292, XP055844468, ISSN: 0003-2700, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/ac5037236> DOI: 10.1021/ac5037236 *
MA WEI ET AL: "Femtogram ultrasensitive aptasensor for the detection of OchratoxinA", BIOSENSORS AND BIOELECTRONICS, vol. 42, 15 April 2013 (2013-04-15), Amsterdam , NL, pages 545 - 549, XP055956638, ISSN: 0956-5663, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0956566312008329/pdfft?md5=0b932ad8c7a62081364858c93b757308&pid=1-s2.0-S0956566312008329-main.pdf> DOI: 10.1016/j.bios.2012.11.024 *
MARGULIES ET AL., NATURE, vol. 437, 2005, pages 376 - 380
NUTIU R ET AL: "Structure-switching signaling aptamers: transducing molecular recognition into fluorescence signaling", CHEMISTRY - A EUROPEAN JOURNAL, JOHN WILEY & SONS, INC, DE, vol. 10, no. 8, 19 April 2004 (2004-04-19), pages 1868 - 1876, XP002374936, ISSN: 0947-6539, DOI: 10.1002/CHEM.200305470 *
SANA RAUF ET AL: "Label-Free Nanopore Biosensor for Rapid and Highly Sensitive Cocaine Detection in Complex Biological Fluids", ACS SENSORS, vol. 2, no. 2, 21 December 2016 (2016-12-21), US, pages 227 - 234, XP055479966, ISSN: 2379-3694, DOI: 10.1021/acssensors.6b00627 *
SINGH NAVEEN K. ET AL: "Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer", MEDRXIV, 2 October 2020 (2020-10-02), XP055907985, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.09.24.20200394v2.full.pdf> [retrieved on 20220401], DOI: 10.1101/2020.09.24.20200394 *
SONI G VMELLER A, CLIN CHEM, vol. 53, 2007, pages 1996 - 2001
YU XIAOCHENG ET AL: "An aptamer-based new method for competitive fluorescence detection of exosomes", NANOSCALE, vol. 11, no. 33, 22 August 2019 (2019-08-22), United Kingdom, pages 15589 - 15595, XP055955599, ISSN: 2040-3364, DOI: 10.1039/C9NR04050A *
ZHAO MENG ET AL: "C4-HSL aptamers for blocking qurom sensing and inhibiting biofilm formation in Pseudomonas aeruginosa and its structure prediction and analysis", PLOS ONE, vol. 14, no. 2, 19 February 1999 (1999-02-19), pages e0212041, XP055957096, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0212041&type=printable> DOI: 10.1371/journal.pone.0212041 *
ZHAO YUANFANG ET AL: "An aptasensor based on the microscopic enumeration of encoding gold nanoparticles for the detection of C-reactive protein", RSC ADVANCES, vol. 9, no. 59, 24 October 2019 (2019-10-24), GB, pages 34293 - 34298, XP055957184, ISSN: 2046-2069, DOI: 10.1039/C9RA06203C *

Similar Documents

Publication Publication Date Title
EP3234602B1 (fr) Procédés d&#39;identification de multiples épitopes dans des sous-populations sélectionnées de cellules
US20230340564A1 (en) Accurate and massively parallel quantification of nucleic acid
Gustafsdottir et al. Proximity ligation assays for sensitive and specific protein analyses
JP4804691B2 (ja) 近接プロービング方法およびキット
JP2007524410A (ja) ポリヌクレオチドライゲーション反応の改良
WO2014126937A1 (fr) Réseaux de suspension et essais multiplexes en fonction de ceux-ci
US9080206B2 (en) Detection of nucleic acids and proteins
US8841095B2 (en) Detection of nucleic acids and proteins
Koch et al. Nanopore sequencing of DNA-barcoded probes for highly multiplexed detection of microRNA, proteins and small biomarkers
JP2022145606A (ja) 核酸の正確な並行定量のための高感度な方法
US8852893B2 (en) Detection of nucleic acids and proteins
US11091803B2 (en) Nucleic acid quantification method
WO2022208171A1 (fr) Procédés de détection d&#39;analytes
FI115139B (fi) Menetelmä ja testipakkaus solu- tai kudosnäytteissä olevien polynukleotidien määrässä tapahtuvien vaihteluiden kvantitatiiviseen ja/tai vertailevaan arvioimiseen
JP2022145605A (ja) 希釈または非精製試料における核酸の正確な並行定量のための方法
CN115605610A (zh) 用于检测不同丰度的分析物的方法
CA3233049A1 (fr) Fluide lymphatique pour diagnostic
US20230002807A1 (en) Methods and compositions for nucleic acid analysis
US20240094213A1 (en) Thoracic duct as a sample collection reservoir
US20230123183A1 (en) Lymphatic fluid for diagnostics
WO2023040997A1 (fr) Procédé de test monogénique et son application
WO2024117954A1 (fr) Procédé et dispositif de détection in vitro
WO2021258024A1 (fr) Détection sensible et multiplexée d&#39;acides nucléiques et de protéines pour un test sérologique à grande échelle
EP4192978A1 (fr) Dosage à analytes multiples pour la détection simultanée d&#39;acide nucléique et d&#39;analytes
JP2024523655A (ja) 核酸分析のための方法および組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22727409

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22727409

Country of ref document: EP

Kind code of ref document: A1